{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:51:59Z","timestamp":1779144719898,"version":"3.51.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8,24]]},"DOI":"10.1097\/qad.0b013e32833c703e","type":"journal-article","created":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T07:50:13Z","timestamp":1278489013000},"page":"2041-2050","source":"Crossref","is-referenced-by-count":51,"title":["Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells\/\u03bcl is associated with improved treatment outcomes in South Africa"],"prefix":"10.1097","volume":"24","author":[{"given":"Matthew P","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M","family":"Sanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Conradie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Zeinecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Orrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence","family":"Ive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Rassool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Dehlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/586712","article-title":"The search for data on when to start treatment for HIV infection","volume":"197","author":"Hughes","year":"2008","journal-title":"J Infect Dis"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.300.5.555","article-title":"Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel","volume":"300","author":"Hammer","year":"2008","journal-title":"JAMA"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.315.7117.1194","article-title":"Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1086\/586713","article-title":"Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study","volume":"197","author":"Emery","year":"2008","journal-title":"J Infect Dis"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/QAD.0b013e328133f285","article-title":"Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies","volume":"21","author":"May","year":"2007","journal-title":"AIDS"},{"key":"R10-8-20210130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/QCO.0b013e328326cd34","article-title":"Should HIV therapy be started at a CD4 cell count above 350 cells\/microl in asymptomatic HIV-1-infected patients?","volume":"22","author":"Sabin","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJM199704103361507","article-title":"Sexual transmission of HIV","volume":"336","author":"Royce","year":"1997","journal-title":"N Engl J Med"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7326\/0003-4819-151-3-200908040-00138","article-title":"When to start antiretroviral therapy in resource-limited settings","volume":"151","author":"Walensky","year":"2009","journal-title":"Ann Intern Med"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","article-title":"Effect of early versus deferred antiretroviral therapy for HIV on survival","volume":"360","author":"Kitahata","year":"2009","journal-title":"N Engl J Med"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bmj.39064.406389.94","article-title":"When should antiretroviral therapy for HIV be started?","volume":"334","author":"Phillips","year":"2007","journal-title":"BMJ"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1001\/jama.286.20.2568","article-title":"Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy","volume":"286","author":"Hogg","year":"2001","journal-title":"JAMA"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1086\/377606","article-title":"When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells\/microl","volume":"37","author":"Kaplan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1097\/QAD.0b013e3282f09876","article-title":"Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa","volume":"21","author":"Moh","year":"2007","journal-title":"AIDS"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/QAD.0b013e3282f768f8","article-title":"Rapid scaling-up of antiretroviral therapy in 10000 adults in Cote d'Ivoire: 2-year outcomes and determinants","volume":"22","author":"Toure","year":"2008","journal-title":"AIDS"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2471\/BLT.07.044248","article-title":"Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries","volume":"86","author":"Brinkhof","year":"2008","journal-title":"Bull World Health Organ"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00002030-200404090-00006","article-title":"Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa","volume":"18","author":"Coetzee","year":"2004","journal-title":"AIDS"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/01.aids.0000226957.79847.d6","article-title":"Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort","volume":"20","author":"Calmy","year":"2006","journal-title":"AIDS"},{"key":"R27-8-20210130","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1097\/QAD.0b013e32830007cd","article-title":"Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa","volume":"22","author":"Lawn","year":"2008","journal-title":"AIDS"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/QAD.0b013e328321823f","article-title":"Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa","volume":"23","author":"Lawn","year":"2009","journal-title":"AIDS"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-138-8-200304150-00018","article-title":"When to start therapy for HIV infection: a swinging pendulum in search of data","volume":"138","author":"Lane","year":"2003","journal-title":"Ann Intern Med"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1002\/sim.1579","article-title":"Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies","volume":"23","author":"Cole","year":"2004","journal-title":"Stat Med"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAD.0b013e32833c703e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:31:34Z","timestamp":1620970294000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002030-201008240-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,24]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e32833c703e","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8,24]]}}}